406 related articles for article (PubMed ID: 35003120)
1. The Activities and Secretion of Cytokines Caused by Delamanid on Macrophages Infected by Multidrug-Resistant
Lyu XL; Lin TT; Gao JT; Jia HY; Zhu CZ; Li ZH; Dong J; Sun Q; Shu W; Pan LP; Zhang ZD; Li Q
Front Immunol; 2021; 12():796677. PubMed ID: 35003120
[TBL] [Abstract][Full Text] [Related]
2. Effects of Bedaquiline on Antimicrobial Activity and Cytokine Secretion of Macrophages Infected with Multidrug-Resistant
Lyu XL; Lin TT; Gao JT; Jia HY; Zhu CZ; Li ZH; Dong J; Sun Q; Shu W; Wang SS; Pan LP; Huang HR; Zhang ZD; Li Q
Can J Infect Dis Med Microbiol; 2022; 2022():2703635. PubMed ID: 35449601
[TBL] [Abstract][Full Text] [Related]
3. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
4. Mycobacterium tuberculosis sRNA MTS2823 regulates the growth of the multidrug-resistant strain in macrophages.
Chen Z; Jiang W; Zhang M; Yu B; Li W; Liu J; Ai F
FEMS Microbiol Lett; 2022 Nov; 369(1):. PubMed ID: 36370448
[TBL] [Abstract][Full Text] [Related]
5. Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans.
Tucker EW; Pieterse L; Zimmerman MD; Udwadia ZF; Peloquin CA; Gler MT; Ganatra S; Tornheim JA; Chawla P; Caoili JC; Ritchie B; Jain SK; Dartois V; Dooley KE
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383662
[TBL] [Abstract][Full Text] [Related]
6. Spontaneous Mutational Patterns and Novel Mutations for Delamanid Resistance in Mycobacterium tuberculosis.
Liu Y; Shi J; Li L; Wu T; Chu P; Pang Y; Guo Y; Gao M; Lu J
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0053122. PubMed ID: 36448833
[TBL] [Abstract][Full Text] [Related]
7. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
Kwon YS; Jeong BH; Koh WJ
Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
[TBL] [Abstract][Full Text] [Related]
8. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.
Blair HA; Scott LJ
Drugs; 2015 Jan; 75(1):91-100. PubMed ID: 25404020
[TBL] [Abstract][Full Text] [Related]
9. Lactic acid bacteria enhance autophagic ability of mononuclear phagocytes by increasing Th1 autophagy-promoting cytokine (IFN-gamma) and nitric oxide (NO) levels and reducing Th2 autophagy-restraining cytokines (IL-4 and IL-13) in response to Mycobacterium tuberculosis antigen.
Ghadimi D; de Vrese M; Heller KJ; Schrezenmeir J
Int Immunopharmacol; 2010 Jun; 10(6):694-706. PubMed ID: 20381647
[TBL] [Abstract][Full Text] [Related]
10. Multidrug Resistant Tuberculosis With Simultaneously Acquired Drug Resistance to Bedaquiline and Delamanid.
Yoshiyama T; Takaki A; Aono A; Mitarai S; Okumura M; Ohta K; Kato S
Clin Infect Dis; 2021 Dec; 73(12):2329-2331. PubMed ID: 32730621
[TBL] [Abstract][Full Text] [Related]
11. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K
Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620
[TBL] [Abstract][Full Text] [Related]
12. Delamanid: first global approval.
Ryan NJ; Lo JH
Drugs; 2014 Jun; 74(9):1041-5. PubMed ID: 24923253
[TBL] [Abstract][Full Text] [Related]
13. Delamanid in the treatment of multidrug-resistant tuberculosis.
Gupta R; Wells CD; Hittel N; Hafkin J; Geiter LJ
Int J Tuberc Lung Dis; 2016 Dec; 20(12):33-37. PubMed ID: 28240570
[TBL] [Abstract][Full Text] [Related]
14. Delamanid for multidrug-resistant pulmonary tuberculosis.
Gler MT; Skripconoka V; Sanchez-Garavito E; Xiao H; Cabrera-Rivero JL; Vargas-Vasquez DE; Gao M; Awad M; Park SK; Shim TS; Suh GY; Danilovits M; Ogata H; Kurve A; Chang J; Suzuki K; Tupasi T; Koh WJ; Seaworth B; Geiter LJ; Wells CD
N Engl J Med; 2012 Jun; 366(23):2151-60. PubMed ID: 22670901
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Transglutaminase 2 as a Potential Host-Directed Therapy Against
Palucci I; Maulucci G; De Maio F; Sali M; Romagnoli A; Petrone L; Fimia GM; Sanguinetti M; Goletti D; De Spirito M; Piacentini M; Delogu G
Front Immunol; 2019; 10():3042. PubMed ID: 32038614
[TBL] [Abstract][Full Text] [Related]
16. Th22 response induced by Mycobacterium tuberculosis strains is closely related to severity of pulmonary lesions and bacillary load in patients with multi-drug-resistant tuberculosis.
Imperiale BR; García A; Minotti A; González Montaner P; Moracho L; Morcillo NS; Palmero DJ; Sasiain MDC; de la Barrera S
Clin Exp Immunol; 2021 Feb; 203(2):267-280. PubMed ID: 33128773
[TBL] [Abstract][Full Text] [Related]
17. Activities of Biapenem against Mycobacterium tuberculosis in Macrophages and Mice.
Guo ZY; Zhao WJ; Zheng MQ; Liu S; Yan CX; Li P; Xu SF
Biomed Environ Sci; 2019 Apr; 32(4):235-241. PubMed ID: 31217059
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains.
Battaglia S; Spitaleri A; Cabibbe AM; Meehan CJ; Utpatel C; Ismail N; Tahseen S; Skrahina A; Alikhanova N; Mostofa Kamal SM; Barbova A; Niemann S; Groenheit R; Dean AS; Zignol M; Rigouts L; Cirillo DM
J Clin Microbiol; 2020 Oct; 58(11):. PubMed ID: 32907992
[TBL] [Abstract][Full Text] [Related]
19. Delamanid for the treatment of pulmonary multidrug-resistant tuberculosis.
Thakare R; Soni I; Dasgupta A; Chopra S
Drugs Today (Barc); 2015 Feb; 51(2):117-23. PubMed ID: 25756067
[TBL] [Abstract][Full Text] [Related]
20. Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent.
Luo W; Huang Z; Xu D; Yang M; Zhu Y; Shen L; Chen S; Tao X; Bin W; Hu Y; Franzblau SG; Jiang N; Wei Y; Wei X; Ding CZ
Bioorg Med Chem Lett; 2022 Sep; 72():128871. PubMed ID: 35777718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
